FibroBiologics (FBLG) Gains from Investment Securities (2024)
FibroBiologics (FBLG) posted quarterly Gains from Investment Securities of -$1.0 million for Q4 2024, up 46.24% on a QoQ basis from -$1.9 million in Q3 2024.
FibroBiologics (FBLG) Gains from Investment Securities (2024) Analysis & Trends
FibroBiologics has reported Gains from Investment Securities for 1 years, with the latest figure at -$1.0 million in Q4 2024.
- Gains from Investment Securities for Q4 2024 came in at -$1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was -$5.4 million (changed N/A YoY), and the FY2024 annual result was -$5.4 million, down 174.42% from the prior year.
- Gains from Investment Securities advanced to -$1.0 million in Q4 2024, from -$1.9 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $3.1 million in Q1 2024 and troughed at -$5.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.04 Mn |
| Dec 31, 2024 | -1.04 Mn |
| Sep 30, 2024 | -1.93 Mn |
| Sep 30, 2024 | -1.93 Mn |
| Jun 30, 2024 | -5.53 Mn |
| Jun 30, 2024 | -5.53 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Mar 31, 2024 | 3.10 Mn |